Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with b-blockers
نویسندگان
چکیده
Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Department of Bioinformatics andComputational Biology, University of TexasMDAnderson Cancer Center, Houston, TX 77030, USA. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Department ofMolecular andCellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. AstraZeneca, Melbourn, SG8 6EE, UK. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Graduate Institute of Oncology, National Taiwan University andNational TaiwanUniversityHospital, Taipei City 100, Taiwan. Solid TumorOncology and Investigational Therapeutics, Levine Cancer Institute Carolinas HealthCare System, Charlotte,NC28204,USA. SectionofMedicalOncology, YaleCancerCenter andSmilow Cancer Hospital, Yale, New Haven, CT 06510, USA. Department of Translational Molecular Pathology, University of TexasMDAndersonCancerCenter, Houston, TX77030, USA. *Corresponding author. Email: [email protected]
منابع مشابه
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance mediated by T790M-independent mechanisms remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). We identified a targetable mechanism of EGFR inhibitor resistance whereby stress hormones activate β2-adrenergic receptors (β2-ARs) on NSCLC cells, which cooperatively signal with mutant EGFR...
متن کاملThe pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion a...
متن کاملProfile of rociletinib and its potential in the treatment of non-small-cell lung cancer
Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients receiving first-generation EGFR inhibitors (erlotinib and gefitinib) develop resistance via the gate...
متن کاملTargeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Preexisting and acquired resistance to epidermal growth factor receptor (EGFR) inhibitors limits their clinical usefulness in patients with advanced non-small cell lung cancer (NSCLC). This study characterizes the efficacy and mechanisms of the combination of gefitinib or erlotinib with OSU-03012, a celecoxib-derived antitumor agent, to overcome EGFR inhibitor resistance in three NSCLC cell lin...
متن کاملRevisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
PURPOSE Single-agent EGFR inhibitor therapy is effective mainly in patients with lung cancer and EGFR mutations. Treating patients who develop resistance, or who are insensitive from the outset, often because of resistant mutations, other aberrations or the lack of an EGFR mutation, probably requires rational combinations. We therefore investigated the outcome of EGFR inhibitor-based combinatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017